去甲长春花碱联合顺铂治疗转移性乳腺癌

Vinorelbine Combined with Cisplatin for Treatment of Patients with Metastatic Breast Carcinoma

目的:观察去甲长春花碱(vinorelbine,NVB)联合顺铂(cisplatin,DDP)治疗转移性乳腺癌的疗效及不良反应。方法:采用NVB25mg/m2dl,8,DDP30mg/m2dl-3,每3周重复一次,共用2-4周期。结果:40例患者中有效率45%(18/40),CR2.5%(1/40),PR42.5%(17/40)。主要剂量限制性不良反应是白细胞减少(Ⅲ、Ⅳ度27.5%)。结论:NVB联合DDP治疗转移性乳腺癌有较好的疗效,且对阿霉素和/或泰素治疗失败的患者亦有较好的疗效,不良反应可耐受。

Objective: This study was designed to investigate the therapeutic effects and toxicity of vinorelbine and cisplatin regimen for treatment of the patients with metastatic breast carcinoma. Method: Forty patients with metastatic breast cancer were treated with combination chemotherapy of vinorelbine 25 mg/m2 d1,8 iv, cisplatin 30 mg/m2 d1-3 iv every 3 weeks. Results: The overall response, complete response, and partial response rate were 45%(18/40), 2.5%(1/40), and 42.5%(17/40), respectively. Dose limiting toxicity (DLT) was leukopenia, 27.5% of cases was in Grade Ⅲ and Grade Ⅳ leucopenia. Conclusions: Vinorelbine combined with cisplatin is effective and has acceptable tolerance in the patients with metastatic breast carcinoma, and also is effective in the patients with metastatic breast carcinoma after failure of adriamycin and/or paclitaxel containing chemotherapy.